glp-1 obesity drugs pipeline Update: November 2024 - Prime Therapeutics Next Generation Obesity Drug Pipeline

But that popularity comes at a high cost

Funding Open access funding provided by Universit Paris-Saclay

But for a long time the company's top managers were highly resistant to pursuing a drug for obesity

N Engl J Med 2022;387:20516.ArticlePubMed 19

Taken together, the prevention of oxidative stress and inflammation is a key mechanism for the renoprotective effects of GLP-1RAs

17,18 Dysregulation of the hypothalamic-pituitary-ovarian axis by hyperandrogenism increases gonadotropin-releasing hormone pulse frequency and is associated with the increased ratio of luteinizing hormone to follicle-stimulating hormone observed in PCOS